Macrogenics Inc financial data

Symbol
MGNX on Nasdaq
Industry
Pharmaceutical Preparations
Location
9704 Medical Center Drive, Rockville, Maryland
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 480 % +13.3%
Quick Ratio 2.39 % -32.3%
Debt-to-equity 91 % -9.7%
Return On Equity -14.9 % +78.9%
Return On Assets -7.8 % +77.9%
Operating Margin -423 % -651%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.4 M shares +0.96%
Common Stock, Shares, Outstanding 62.6 M shares +1.17%
Entity Public Float 323 M USD +77.9%
Common Stock, Value, Issued 626 K USD +1.29%
Weighted Average Number of Shares Outstanding, Basic 62.3 M shares +0.78%
Weighted Average Number of Shares Outstanding, Diluted 62.3 M shares +0.78%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 43.4 M USD -73.8%
Research and Development Expense 167 M USD -12.9%
General and Administrative Expense 53.4 M USD -5.07%
Costs and Expenses 227 M USD -12.2%
Operating Income (Loss) -184 M USD -96.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -23.2 M USD +74.6%
Earnings Per Share, Basic -0.38 USD/shares +74.3%
Earnings Per Share, Diluted -0.38 USD/shares +74.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 80.4 M USD -64.2%
Accounts Receivable, after Allowance for Credit Loss, Current 7.22 M USD -80%
Inventory, Net 1.25 M USD -11.4%
Assets, Current 203 M USD -29.9%
Property, Plant and Equipment, Net 21.3 M USD -20.5%
Operating Lease, Right-of-Use Asset 23.2 M USD -12%
Other Assets, Noncurrent 1.19 M USD -14%
Assets 248 M USD -27.7%
Accounts Payable, Current 10.7 M USD +184%
Accrued Liabilities, Current 18.1 M USD -35.6%
Contract with Customer, Liability, Current 22.8 M USD +147%
Liabilities, Current 55.8 M USD +22.3%
Contract with Customer, Liability, Noncurrent 56.2 M USD -3.15%
Operating Lease, Liability, Noncurrent 29.9 M USD -0.67%
Other Liabilities, Noncurrent 258 K USD 0%
Liabilities 142 M USD -39.3%
Retained Earnings (Accumulated Deficit) -1.15 B USD -2.05%
Stockholders' Equity Attributable to Parent 106 M USD -2.85%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 106 M USD -2.85%
Liabilities and Equity 248 M USD -27.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.6 M USD -256%
Net Cash Provided by (Used in) Financing Activities 248 K USD -99.8%
Net Cash Provided by (Used in) Investing Activities 24.8 M USD -11.7%
Common Stock, Shares Authorized 125 M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -20.6 M USD -118%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 80.4 M USD -64.2%
Deferred Tax Assets, Valuation Allowance 365 M USD -1.95%
Deferred Tax Assets, Gross 373 M USD -2.07%
Operating Lease, Liability 34 M USD -2.48%
Depreciation 9.6 M USD -19.3%
Payments to Acquire Property, Plant, and Equipment 1.46 M USD +306%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -23.3 M USD +74.4%
Lessee, Operating Lease, Liability, to be Paid 70.3 M USD -6.64%
Property, Plant and Equipment, Gross 110 M USD -3.01%
Operating Lease, Liability, Current 4.09 M USD -7.54%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.08 M USD +27%
Lessee, Operating Lease, Liability, to be Paid, Year One 4 M USD -19.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 36.3 M USD -10.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.21 M USD -17.2%
Current Income Tax Expense (Benefit) 0 USD
Unrecognized Tax Benefits 7.82 M USD +6.03%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.93 M USD +17.1%
Operating Lease, Payments 5.9 M USD -14.5%
Depreciation, Depletion and Amortization 1.84 M USD -38.3%
Deferred Tax Assets, Net of Valuation Allowance 8.4 M USD -7.09%
Share-based Payment Arrangement, Expense 19.1 M USD -4.52%
Interest Expense 1.91 M USD +72.7%